Evidence map›Paper›PMID 41179290›Full record

ArticleOncology research2025

Investigation on the Anti-Cancer Effects of HER2-Targeted CAR-T Cells Engineered Using the

Tian-Tian Li, Ming-Yao Meng, Zheng Yu, Yang-Fan Guo, Yi-Yi Zhao, Hui Gao, Li-Li Yang, Li-Rong Yang, Meng-Yuan Chu, Shan He and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tian-Tian LiCentral Laboratory, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, 650051, China.
Ming-Yao MengCentral Laboratory, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, 650051, China.
Zheng YuSchool of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China.
Yang-Fan GuoCentral Laboratory, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, 650051, China.
Yi-Yi ZhaoCentral Laboratory, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, 650051, China.
Hui GaoCentral Laboratory, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, 650051, China.
Li-Li YangCentral Laboratory, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, 650051, China.
Li-Rong YangCentral Laboratory, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, 650051, China.
Meng-Yuan ChuCentral Laboratory, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, 650051, China.
Shan HeCentral Laboratory, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, 650051, China.
Yuan LiuCentral Laboratory, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, 650051, China.
Xiao-Dan WangCentral Laboratory, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, 650051, China.
Wen-Ju WangCentral Laboratory, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, 650051, China.
Zong-Liu HouCentral Laboratory, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, 650051, China.
Li-Wei LiaoCentral Laboratory, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, 650051, China.
Lin LiCentral Laboratory, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, 650051, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chimeric antigen receptor T (CAR-T) cell therapies have demonstrated significant clinical efficacy in hematological malignancies. However, their application to solid tumors remains substantially limited by multiple challenges, including the risk of off-target effects. Hence, optimizing CAR-T cells for stronger antigen binding is essential. Methods: In this study, we employed a classical anti-human endothelial growth factor receptor 2 (HER2) single-chain variable fragment (scFv) derived from trastuzumab, alongside an anti-HER2-13 scFv identified from a combinatorial cellular CAR library, for the construction of a third-generation CAR-T cell. Meanwhile, the phenotypes and both Results: The optimal ratio between the Conclusion: These results highlight the potential of anti-HER2-13 CAR-T cells to serve as a safer and more efficacious alternative in HER2-targeted therapy.

Indexed as

DNA Transposable ElementsErb-b2 Receptor Tyrosine KinasesImmunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesAnimalsCell Line, TumorFemaleHumansMiceSingle-Chain AntibodiesXenograft Model Antitumor AssaysDNA Transposable ElementsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, Chimeric AntigenSingle-Chain Antibodiescell therapyChimeric antigen receptor Thuman endothelial growth factor receptor 2PiggyBac transposase

Identifiers

PMID41179290
PMCPMC12573187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.